The University of Southampton
University of Southampton Institutional Repository

The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis

The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis
The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive disease that usually affects elderly people. It has a poor prognosis and there are limited therapies. Since epigenetic alterations are associated with IPF, histone deacetylase (HDAC) inhibitors offer a novel therapeutic strategy to address the unmet medical need. This study investigated the potential of romidepsin, an FDA-approved HDAC inhibitor, as an anti-fibrotic treatment and evaluated biomarkers of target engagement that may have utility in future clinical trials. The anti-fibrotic effects of romidepsin were evaluated both in vitro and in vivo together with any harmful effect on alveolar type II cells (ATII). Bronchoalveolar lavage fluid (BALF) from IPF or control donors was analyzed for the presence of lysyl oxidase (LOX). In parallel with an increase in histone acetylation, romidepsin potently inhibited fibroblast proliferation, myofibroblast differentiation and LOX expression. ATII cell numbers and their lamellar bodies were unaffected. In vivo, romidepsin inhibited bleomycin-induced pulmonary fibrosis in association with suppression of LOX expression. LOX was significantly elevated in BALF of IPF patients compared to controls. These data show the anti-fibrotic effects of romidepsin, supporting its potential use as novel treatment for IPF with LOX as a companion biomarker for evaluation of early on-target effects.
1949-2553
48737-48754
Conforti, Franco
28bf123c-e42a-4fb5-8b26-f79e1095c586
Davies, Elizabeth R.
aff6b3f7-91e0-4fd3-9554-a9389024b63b
Calderwood, Claire J.
824fa5e6-7595-4d6a-bfce-5c2ec551ac42
Thatcher, Thomas H.
b4138c92-d1b3-41a8-9991-3374f68ac516
Jones, Mark G.
a6fd492e-058e-4e84-a486-34c6035429c1
Smart, David E.
3468eafa-5280-40a1-9fda-1bdc07dd914f
Mahajan, Sumeet
b131f40a-479e-4432-b662-19d60d4069e9
Alzetani, Aiman
04d65796-5c8e-4c5b-aeeb-ea093c118f03
Havelock, Tom
8f9aa3be-a768-4a7b-bcd4-79656e2b188c
Maher, Toby M.
6c166764-7a4e-4d20-b528-381a7218ea0b
Molyneaux, Philip L.
9761b4a9-5539-4683-a023-af7e351365ee
Thorley, Andrew J.
106457f1-90a7-4a3d-9963-5a16cc8cfe66
Tetley, Teresa D.
85489d1b-9012-451c-97f2-82368c9dd081
Warner, Jane A.
8571b049-31bb-4a2a-a3c7-4184be20fe25
Packham, Graham
fdabe56f-2c58-469c-aadf-38878f233394
Ganesan, A.
8453180c-2d4a-4415-b675-192df230a7b9
Skipp, Paul J.
1ba7dcf6-9fe7-4b5c-a9d0-e32ed7f42aa5
Marshall, Benjamin J.
9abf382c-977f-459c-9b91-5ed8cbf2284f
Richeldi, Luca
47177d9c-731a-49a1-9cc6-4ac8f6bbbf26
Sime, Patricia J.
d96733e9-a51c-4dc0-90c0-203e550827d1
O'Reilly, Katherine M.A.
6c323cd0-0c68-4913-9666-7e4f655b816f
Davies, Donna E.
7de8fdc7-3640-4e3a-aa91-d0e03f990c38
Conforti, Franco
28bf123c-e42a-4fb5-8b26-f79e1095c586
Davies, Elizabeth R.
aff6b3f7-91e0-4fd3-9554-a9389024b63b
Calderwood, Claire J.
824fa5e6-7595-4d6a-bfce-5c2ec551ac42
Thatcher, Thomas H.
b4138c92-d1b3-41a8-9991-3374f68ac516
Jones, Mark G.
a6fd492e-058e-4e84-a486-34c6035429c1
Smart, David E.
3468eafa-5280-40a1-9fda-1bdc07dd914f
Mahajan, Sumeet
b131f40a-479e-4432-b662-19d60d4069e9
Alzetani, Aiman
04d65796-5c8e-4c5b-aeeb-ea093c118f03
Havelock, Tom
8f9aa3be-a768-4a7b-bcd4-79656e2b188c
Maher, Toby M.
6c166764-7a4e-4d20-b528-381a7218ea0b
Molyneaux, Philip L.
9761b4a9-5539-4683-a023-af7e351365ee
Thorley, Andrew J.
106457f1-90a7-4a3d-9963-5a16cc8cfe66
Tetley, Teresa D.
85489d1b-9012-451c-97f2-82368c9dd081
Warner, Jane A.
8571b049-31bb-4a2a-a3c7-4184be20fe25
Packham, Graham
fdabe56f-2c58-469c-aadf-38878f233394
Ganesan, A.
8453180c-2d4a-4415-b675-192df230a7b9
Skipp, Paul J.
1ba7dcf6-9fe7-4b5c-a9d0-e32ed7f42aa5
Marshall, Benjamin J.
9abf382c-977f-459c-9b91-5ed8cbf2284f
Richeldi, Luca
47177d9c-731a-49a1-9cc6-4ac8f6bbbf26
Sime, Patricia J.
d96733e9-a51c-4dc0-90c0-203e550827d1
O'Reilly, Katherine M.A.
6c323cd0-0c68-4913-9666-7e4f655b816f
Davies, Donna E.
7de8fdc7-3640-4e3a-aa91-d0e03f990c38

Conforti, Franco, Davies, Elizabeth R., Calderwood, Claire J., Thatcher, Thomas H., Jones, Mark G., Smart, David E., Mahajan, Sumeet, Alzetani, Aiman, Havelock, Tom, Maher, Toby M., Molyneaux, Philip L., Thorley, Andrew J., Tetley, Teresa D., Warner, Jane A., Packham, Graham, Ganesan, A., Skipp, Paul J., Marshall, Benjamin J., Richeldi, Luca, Sime, Patricia J., O'Reilly, Katherine M.A. and Davies, Donna E. (2017) The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis. Oncotarget, 8 (30), 48737-48754. (doi:10.18632/oncotarget.17114).

Record type: Article

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive disease that usually affects elderly people. It has a poor prognosis and there are limited therapies. Since epigenetic alterations are associated with IPF, histone deacetylase (HDAC) inhibitors offer a novel therapeutic strategy to address the unmet medical need. This study investigated the potential of romidepsin, an FDA-approved HDAC inhibitor, as an anti-fibrotic treatment and evaluated biomarkers of target engagement that may have utility in future clinical trials. The anti-fibrotic effects of romidepsin were evaluated both in vitro and in vivo together with any harmful effect on alveolar type II cells (ATII). Bronchoalveolar lavage fluid (BALF) from IPF or control donors was analyzed for the presence of lysyl oxidase (LOX). In parallel with an increase in histone acetylation, romidepsin potently inhibited fibroblast proliferation, myofibroblast differentiation and LOX expression. ATII cell numbers and their lamellar bodies were unaffected. In vivo, romidepsin inhibited bleomycin-induced pulmonary fibrosis in association with suppression of LOX expression. LOX was significantly elevated in BALF of IPF patients compared to controls. These data show the anti-fibrotic effects of romidepsin, supporting its potential use as novel treatment for IPF with LOX as a companion biomarker for evaluation of early on-target effects.

Text
17114-250869-3-PB - Version of Record
Available under License Creative Commons Attribution.
Download (3MB)

More information

Accepted/In Press date: 3 April 2017
e-pub ahead of print date: 14 April 2017
Published date: 14 April 2017
Organisations: Cancer Sciences, Institute for Life Sciences, Allergy & Inflammation Research, Support Staff - Technical, Clinical & Experimental Sciences

Identifiers

Local EPrints ID: 408662
URI: http://eprints.soton.ac.uk/id/eprint/408662
ISSN: 1949-2553
PURE UUID: d7629908-13de-4b7a-8fd2-85f68aacf39c
ORCID for Elizabeth R. Davies: ORCID iD orcid.org/0000-0002-8629-8324
ORCID for Mark G. Jones: ORCID iD orcid.org/0000-0001-6308-6014
ORCID for Sumeet Mahajan: ORCID iD orcid.org/0000-0001-8923-6666
ORCID for Graham Packham: ORCID iD orcid.org/0000-0002-9232-5691
ORCID for Paul J. Skipp: ORCID iD orcid.org/0000-0002-2995-2959
ORCID for Donna E. Davies: ORCID iD orcid.org/0000-0002-5117-2991

Catalogue record

Date deposited: 25 May 2017 04:03
Last modified: 16 Mar 2024 04:02

Export record

Altmetrics

Contributors

Author: Franco Conforti
Author: Claire J. Calderwood
Author: Thomas H. Thatcher
Author: Mark G. Jones ORCID iD
Author: David E. Smart
Author: Sumeet Mahajan ORCID iD
Author: Aiman Alzetani
Author: Tom Havelock
Author: Toby M. Maher
Author: Philip L. Molyneaux
Author: Andrew J. Thorley
Author: Teresa D. Tetley
Author: Jane A. Warner
Author: Graham Packham ORCID iD
Author: A. Ganesan
Author: Paul J. Skipp ORCID iD
Author: Luca Richeldi
Author: Patricia J. Sime
Author: Katherine M.A. O'Reilly
Author: Donna E. Davies ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×